drugset / Trial / NCT06617858
Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment
NaSingle-groupOpen-labelTreatment
Summary
To investigate the efficacy of AMB-05X in patients with CRC with MRD as determined by a ctDNA(+) blood test and no clinically detectable radiographic disease.
Timeline
- Start
- 2024-12-04
- Primary completion
- 2028-02-01
- Completion
- 2028-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AMB-05X | Monoclonal antibody | — | Intravenous |